Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in adults with prurigo nodularis inadequately controlled on topical therapies
2019-003774-41Phase 3Completed
- Sponsor
- Sanofi
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prurigo nodularis (PN) comparing Dupilumab with Placebo (2 arms). Primary endpoint: Improvement in worst-itch numeric rating scale by at least 4 points at Week 12. Started Feb 2021; status: completed.
02
Drugs
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on 2019-003774-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003774-41.